<DOC>
	<DOCNO>NCT01011205</DOCNO>
	<brief_summary>Comparison 3 dose regimen Advagraf determine dose regimen may potential cause few kidney problem .</brief_summary>
	<brief_title>Phase 3b Study Evaluate Advagraf Combination With Mycophenolate Mofetil Basiliximab Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Undergoing orthotopic liver split liver allograft transplantation Female subject childbearing potential must negative serum urine pregnancy test enrollment must agree maintain effective birth control study Receiving multiorgan transplant previous receive organ transplant ( include liver retransplantation ) Receiving auxiliary graft bioartificial liver ( cell system ) use Receiving ABO incompatible graft graft non heart beat donor Ongoing dose systemic corticosteroid Subjects systemic infection require treatment except viral hepatitis Diagnosis newonset malignancy prior transplantation , exception basocellular squamous cell carcinoma skin treat successfully . However , subject primary liver carcinoma include meet follow criterion : &lt; 3 node node large 5 cm metastasis vascular tumoral invasion Significant , uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer Subject donor know HIV positive Known allergy intolerance tacrolimus , macrolide antibiotic , corticosteroid , basiliximab mycophenolate mofetil product excipients Pregnant woman breastfeed mother Currently participate another clinical trial , and/or take investigational drug within 28 day prior enrollment Unlikely comply Visits schedule protocol Any unstable medical condition could interfere study objective opinion Investigator Receiving prohibit concomitant therapy , receive prohibit concomitant therapy within 28 day prior enrollment Any form substance abuse , psychiatric disorder condition , opinion Investigator , may complicate communication Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Advagraf</keyword>
	<keyword>Liver</keyword>
	<keyword>Transplant</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>